News - regorafenib, Research


Current filters:


Popular Filters

News briefs: US priority review for regorafenib; Ph IIb blisibimod data


Bayer HealthCare, a US unit of Germany's Bayer (BAYN: DE) and partner Onyx Pharmaceuticals (Nasdaq: ONXX)…

Anthera PharmaceuticalsBayerBiotechnologyblisibimodOncologyOnyx PharmaceuticalsPharmaceuticalRare diseasesregorafenibRegulationResearch

More news from ASCO meeting


More positive late-stage clinical data continued to roll out at the Annual Meeting of the American Society…

AlimtaBayerdabrafenibEli LillyGlaxoSmithKlineOncologyPharmaceuticalregorafenibResearchtrametinib

News briefs: GlaxoSmithKline and Bayer


UK pharma giant GlaxoSmithKline (LSE: GSK) has said it would not proceed with its $2.59 billion hostile…

Antibiotics and Infectious diseasesBayerGlaxoSmithKlineMergers & AcquisitionsOncologyPharmaceuticalregorafenibRegulationResearch

Bayer cancer drug candidate regorafenib improves survival in GIST


German drug major Bayer (BAY: DE) yesterday announced positive results from its Phase III trial GRID…


Bayer’s Xarelto OKed in Japan; promising regorafenib data


Bayer Healthcare, a unit of Germany’s Bayer AG (BAY: DE), had a couple of good news item to report…

BayerCardio-vascularOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationResearchXarelto

Bayer boasts four potential pipeline blockbusters


German drugs and crop and material sciences group Bayer (BAT: DE) said yesterday that it plans to continue…

AlpharadinBayerCardio-vascularEyleaFinancialMarkets & MarketingOncologyOphthalmicsPharmaceuticalregorafenibResearchXarelto

Bayer halts regorafenib trial for colorectal cancer on good Ph III results


USA-based Bayer HealthCare Pharmaceuticals, a subsidiary of Germany’s Bayer AG (BAY: DE), has announced…

BayerOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibResearch

Back to top